Alto Neuroscience Inc (ANRO)

$21.47 -0.57 (-2.59%)
Market Cap 719.42M
Revenue (ttm) 0.00
Net Income (ttm) -61.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.18
Volume 423,500
Avg Vol 233,184
Day's Range N/A - N/A
Shares Out 31.95M
Stochastic %K 20%
Beta 2.52
Analysts Strong Sell
Price Target $36.00

Company Profile

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule ph...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 200 0412
Address:
650 Castro Street, Suite 450, Mountain View, United States
anachartanalyst
anachartanalyst Mar. 18 at 3:02 PM
$ANRO https://anachart.com/wp-content/uploads/ana_temp/1773846097_soc-img.jpg
0 · Reply
erevnon
erevnon Mar. 18 at 2:33 PM
Baird maintains Alto Neuroscience $ANRO at Outperform and raises the price target from $22 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
erevnon
erevnon Mar. 17 at 2:27 PM
Wedbush maintains Alto Neuroscience $ANRO at Neutral and raises the price target from $13 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
LewisDaKat
LewisDaKat Mar. 17 at 10:00 AM
$ANRO Expected earnings - Alto Neuroscience Inc. https://marketwirenews.com/stock/anro/news/expected-earnings-alto-neuroscience-inc--6717088496715488.html?utm_source=stocktwits
0 · Reply
StockConsultant
StockConsultant Mar. 16 at 4:05 PM
$ANRO Alto Neuroscience stock, nice continuation breakout, from Stocks to Watch at https://stockconsultant.com/?ANRO
0 · Reply
Ccperk
Ccperk Mar. 15 at 11:10 PM
$ANRO Potentially big week this week, we will 👀
0 · Reply
cea
cea Mar. 12 at 2:09 AM
$ANRO $LWLG $RILY $SLS I don’t know ANY $SLS investors jumping into anything other than $SLS. That would be absolutely insane.
4 · Reply
WangSLO
WangSLO Mar. 12 at 12:52 AM
$ANRO $SLS $RILY $LWLG and the discord "trading groups" are here ...
3 · Reply
CARTE_BLANCHE_DEVEREAUX
CARTE_BLANCHE_DEVEREAUX Mar. 12 at 12:38 AM
$ANRO $SLS $RILY $LWLG Lots of multi-baggers this year already... WE CALLED LWLG LAST NIGHT IN THE DISCORD CALL (ITS UP ON YOUTUBE) ANRO CONTINUING, CING GOING, ANNA WENT... RILY is on deck. I know a lot of the SELLAS fam are jumping in...hoping this one launches some ports. How we are doing this isnt pumps... It's a large group actually working together to see targets... Instead of talking BS on this "forum". Work together y'all A Rising Tide Raises All Ships
0 · Reply
Stackdoe101
Stackdoe101 Mar. 11 at 3:20 PM
$ASNS $ARTV $AMPX $EKSO $ANRO
0 · Reply
Latest News on ANRO
Alto Neuroscience Announces $120 Million Private Placement Financing

Mar 16, 2026, 7:03 AM EDT - 5 days ago

Alto Neuroscience Announces $120 Million Private Placement Financing

Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights

Mar 16, 2026, 6:03 AM EDT - 5 days ago

Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights

Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum

Mar 13, 2026, 8:03 AM EDT - 8 days ago

Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

Feb 23, 2026, 8:33 AM EST - 26 days ago

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia

Feb 13, 2026, 8:04 AM EST - 5 weeks ago

Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia

Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment

Feb 3, 2026, 8:27 AM EST - 6 weeks ago

Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment

Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression

Jan 14, 2026, 7:27 AM EST - 2 months ago

Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression

Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology

Jan 13, 2026, 8:00 AM EST - 2 months ago

Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology

Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08

Dec 3, 2025, 4:05 PM EST - 3 months ago

Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08

Alto Neuroscience: 4 Shots At Success In CNS Diseases In 2026

Nov 28, 2025, 12:38 PM EST - 4 months ago

Alto Neuroscience: 4 Shots At Success In CNS Diseases In 2026

Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 12, 2025, 7:57 AM EST - 4 months ago

Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Alto Neuroscience to Participate in Upcoming Investor Conferences

Oct 28, 2025, 7:34 AM EDT - 5 months ago

Alto Neuroscience to Participate in Upcoming Investor Conferences

Alto Neuroscience Announces $50 Million Private Placement Financing

Oct 20, 2025, 7:03 AM EDT - 5 months ago

Alto Neuroscience Announces $50 Million Private Placement Financing

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

Oct 20, 2025, 7:01 AM EDT - 5 months ago

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Oct 8, 2025, 9:56 AM EDT - 5 months ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Oct 3, 2025, 10:51 AM EDT - 6 months ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

Oct 3, 2025, 7:34 AM EDT - 6 months ago

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Sep 13, 2025, 11:50 AM EDT - 6 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia

Sep 9, 2025, 7:09 AM EDT - 6 months ago

Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Aug 28, 2025, 5:40 PM EDT - 7 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Aug 22, 2025, 10:15 AM EDT - 7 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Alto Neuroscience, Inc. (NYSE: ANRO) between Feb. and Oct. 2024 should contact the Shareholders Foundation

Aug 18, 2025, 9:45 AM EDT - 7 months ago

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Alto Neuroscience, Inc. (NYSE: ANRO) between Feb. and Oct. 2024 should contact the Shareholders Foundation

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. Lawsuit - ANRO

Aug 18, 2025, 8:45 AM EDT - 7 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. Lawsuit - ANRO

Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 13, 2025, 4:10 PM EDT - 7 months ago

Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

Aug 13, 2025, 8:03 AM EDT - 7 months ago

Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

Alto Neuroscience, Inc. Investigated for Breaches of Fiduciary Duty - Contact the DJS Law Group to Discuss Your Rights – ANRO

Aug 4, 2025, 2:46 PM EDT - 8 months ago

Alto Neuroscience, Inc. Investigated for Breaches of Fiduciary Duty - Contact the DJS Law Group to Discuss Your Rights – ANRO

ALTO NEUROSCIENCE, INC. (NYSE: ANRO) INVESTOR ALERT Investors With Large Losses in Alto Neuroscience, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Jul 22, 2025, 6:25 PM EDT - 8 months ago

ALTO NEUROSCIENCE, INC. (NYSE: ANRO) INVESTOR ALERT Investors With Large Losses in Alto Neuroscience, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

Jun 30, 2025, 8:03 AM EDT - 9 months ago

Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

Jun 26, 2025, 7:33 AM EDT - 9 months ago

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

Jun 3, 2025, 6:03 AM EDT - 10 months ago

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder

May 29, 2025, 8:03 AM EDT - 10 months ago

Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder

Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 14, 2025, 4:10 PM EDT - 11 months ago

Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights

Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach

Apr 28, 2025, 8:03 AM EDT - 11 months ago

Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach

anachartanalyst
anachartanalyst Mar. 18 at 3:02 PM
$ANRO https://anachart.com/wp-content/uploads/ana_temp/1773846097_soc-img.jpg
0 · Reply
erevnon
erevnon Mar. 18 at 2:33 PM
Baird maintains Alto Neuroscience $ANRO at Outperform and raises the price target from $22 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
erevnon
erevnon Mar. 17 at 2:27 PM
Wedbush maintains Alto Neuroscience $ANRO at Neutral and raises the price target from $13 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
LewisDaKat
LewisDaKat Mar. 17 at 10:00 AM
$ANRO Expected earnings - Alto Neuroscience Inc. https://marketwirenews.com/stock/anro/news/expected-earnings-alto-neuroscience-inc--6717088496715488.html?utm_source=stocktwits
0 · Reply
StockConsultant
StockConsultant Mar. 16 at 4:05 PM
$ANRO Alto Neuroscience stock, nice continuation breakout, from Stocks to Watch at https://stockconsultant.com/?ANRO
0 · Reply
Ccperk
Ccperk Mar. 15 at 11:10 PM
$ANRO Potentially big week this week, we will 👀
0 · Reply
cea
cea Mar. 12 at 2:09 AM
$ANRO $LWLG $RILY $SLS I don’t know ANY $SLS investors jumping into anything other than $SLS. That would be absolutely insane.
4 · Reply
WangSLO
WangSLO Mar. 12 at 12:52 AM
$ANRO $SLS $RILY $LWLG and the discord "trading groups" are here ...
3 · Reply
CARTE_BLANCHE_DEVEREAUX
CARTE_BLANCHE_DEVEREAUX Mar. 12 at 12:38 AM
$ANRO $SLS $RILY $LWLG Lots of multi-baggers this year already... WE CALLED LWLG LAST NIGHT IN THE DISCORD CALL (ITS UP ON YOUTUBE) ANRO CONTINUING, CING GOING, ANNA WENT... RILY is on deck. I know a lot of the SELLAS fam are jumping in...hoping this one launches some ports. How we are doing this isnt pumps... It's a large group actually working together to see targets... Instead of talking BS on this "forum". Work together y'all A Rising Tide Raises All Ships
0 · Reply
Stackdoe101
Stackdoe101 Mar. 11 at 3:20 PM
$ASNS $ARTV $AMPX $EKSO $ANRO
0 · Reply
StockConsultant
StockConsultant Mar. 10 at 12:04 PM
$ANRO Alto Neuroscience stock with a top of range breakout at https://stockconsultant.com/?ANRO
0 · Reply
Ccperk
Ccperk Mar. 2 at 5:56 PM
$ANRO This months anticipated Topline data/Readout for the fast tracked ALTO-101 is absolutely critical for this company. Price in the 20s and I speculate will see saw from here.
0 · Reply
rsheth76
rsheth76 Mar. 2 at 4:54 PM
$ANRO When?
0 · Reply
Stef_DL
Stef_DL Mar. 2 at 3:56 PM
$ANRO My god, we just broke 20+.
0 · Reply
StockConsultant
StockConsultant Mar. 2 at 12:22 AM
$ANRO Alto Neuroscience stock, watch for a top of range breakout above 20.79 at https://stockconsultant.com/?ANRO
2 · Reply
rsheth76
rsheth76 Feb. 27 at 7:52 PM
$ANRO When is the next data coming? Q1 or Q2?
0 · Reply
optionravi
optionravi Feb. 20 at 4:10 PM
$ANRO Alto Neuroscience develops precision psychiatry treatments. Valuation is driven by clinical data and biomarker validation. Early-stage risk remains high.
0 · Reply
MOOSEN
MOOSEN Feb. 18 at 12:03 AM
$ANRO SO WHAT DA FUH?
0 · Reply
CARTE_BLANCHE_DEVEREAUX
CARTE_BLANCHE_DEVEREAUX Feb. 17 at 9:47 PM
$ANRO $ALT $PYPD When I first bought into ANRO, I thought I was being reckless. I worried that I had bought too much... Now.... I realize I didn't buy enough. Won't make the same mistake with POLYPID.
0 · Reply
Ccperk
Ccperk Feb. 17 at 9:37 PM
$ANRO love seeing all the 13/Gs pouring in. It appears confidence is through the roof.
0 · Reply
erevnon
erevnon Feb. 17 at 11:17 AM
BTIG maintains Alto Neuroscience $ANRO at Buy and raises the price target from $27 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply